secwatch.observer — SEC 8-K summary
======================================

Issuer:     INTERPACE BIOSCIENCES, INC. (IDXG)
CIK:        0001054102
Form:       8-K
Filed at:   2025-08-08T23:59:59+00:00
Accession:  0001641172-25-022774
Event type: earnings
Sentiment:  negative
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Interpace Biosciences Q2 revenue down 23% to $9.2M; loss from continuing ops $0.5M
--------------------------------------------------------------------------------

- Net revenue $9.2M (-23% YoY); loss from continuing ops $0.5M vs income $2.5M a year ago.
- Thyroid test volume up 16% YoY; thyroid revenue $8.7M (+25% YoY) to record levels.
- Gross margin 57% (65% ex one-time PancraGEN impact); adjusted EBITDA $0.4M vs $2.8M.
- One-time charge $1.2M from PancraGEN reimbursement loss; company winding down test.
- Preliminary July 2025 revenue $3.3M (+54% YoY); management sees Q3 improvement.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1054102/000164117225022774/0001641172-25-022774-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1054102/000164117225022774/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001641172-25-022774

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer